Global Advanced Molecular Nuclear Imaging Market Size, Share, and COVID-19 Impact Analysis, By Product (SPECT Systems and Hybrid PET Systems Planar Scintigraphy), By Application (Oncology, Cardiology, Neurology, and Others), By End User (Hospitals, Imaging Centers, Academic and Research Centers, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 - 2035

Global Advanced Molecular Nuclear Imaging Market Size Insights Forecasts to 2035

• The Global Advanced Molecular Nuclear Imaging Market Size Was Estimated at USD 5.37 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of around 5.42% from 2025 to 2035
• The Worldwide Advanced Molecular Nuclear Imaging Market Size is Expected to Reach USD 9.60 Billion by 2035
• Asia Pacific is expected to grow the fastest during the forecast period.

According to a Research Report Published by Spherical Insights and Consulting, The Global Advanced Molecular Nuclear Imaging Market Size was worth around USD 5.37 Billion in 2024 and is predicted to grow to around USD 9.60 Billion by 2035 with a compound annual growth rate (CAGR) of 5.42% from 2025 and 2035. The market for advanced molecular nuclear imaging has a number of opportunities to grow due to the adoption of advancements (PET/CT, SPECT/CT) and expanding infrastructure & investment.

Market Overview

The global advanced molecular nuclear imaging industry encompasses the high-precision, non-invasive diagnostic technologies, specifically PET and SPECT combined with CT or MRI to visualize biological processes at the cellular level, primarily for oncology, cardiology, and neurology. An increasing need for early disease detection, AI integration, and targeted radiopharmaceuticals is driving the growth of the advanced molecular nuclear imaging market for personalized medicine and improved patient outcomes. Advanced molecular nuclear imaging allows visualizing patients at the cellular and molecular levels for locating the disease, better understanding disease pathways, improving therapy selection, and monitoring patient response to treatment.

Innovation and market expansion are anticipated as a result of major players' growing R&D expenditures and the expanding partnerships. For instance, in March 2026, MedGenome announced a majority investment in Mumbai-headquartered Medcare Management Services Pvt. Ltd., a radiology and nuclear medicine company known for its PET-CT and advanced molecular imaging services.

Report Coverage

This research report categorizes the advanced molecular nuclear imaging market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the advanced molecular nuclear imaging market. Recent market developments and competitive strategies such as expansion, type launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the advanced molecular nuclear imaging market. 

Driving Factors

The market of advanced molecular nuclear imaging is primarily driven by the continuous ongoing advancement in precision care to help support early diagnosis, tailored treatments and improved patient outcomes. Integration of artificial intelligence (AI) and machine learning for enhancing image interpretation, improving diagnostic precision, and speeding up analysis, with an increasing emphasis on developing advanced technologies are promoting the market growth of advanced molecular nuclear imaging. In addition, surging focus on personalized medicine and early disease detection, highlighting the significance of molecular nuclear imaging in tailored healthcare solutions, is promoting the market growth of advanced molecular nuclear imaging.

Restraining Factors

The advanced molecular nuclear imaging market is restricted by factors such as increased equipment cost and limited availability of trained professionals. Further, the increased capital investment for PET/CT and SPECT systems, expensive radiopharmaceutical procurement, and specialized staff training are challenging the market.

Market Segmentation

The advanced molecular nuclear imaging market share is classified into product, application, and end user.  

• The SPECT systems segment dominated the market with a substantial share of about 56.5% in 2024 and is projected to grow at a substantial CAGR during the forecast period.

Based on the product, the advanced molecular nuclear imaging market is divided into SPECT systems and hybrid PET systems planar scintigraphy. Among these, the SPECT systems segment dominated the market with a substantial share of about 56.5% in 2024 and is projected to grow at a substantial CAGR during the forecast period. SPECT (Single Photon Emission Computed Tomography) scan imaging test uses radiotracers and a special camera for taking detailed, 3D pictures of the organs, tissues and bones inside the body. Its widespread application in the diagnosis of cardiovascular diseases, cancers, and neurological disorders is driving the segmental market.

• The oncology segment accounted for the largest share of about 38.5% in 2024 and is anticipated to grow at a significant CAGR during the forecast period.

Based on the application, the advanced molecular nuclear imaging market is divided into oncology, cardiology, neurology, and others. Among these, the oncology segment accounted for the largest share of about 38.5% in 2024 and is anticipated to grow at a significant CAGR during the forecast period. For instance, molecular imaging, especially combined with liquid biopsy enable early localization of disease, like the appearance of metastases, for optimum management. An increasing demand for precise visualization of tumors and their metabolic activity for enhancing early detection and personalized treatment plans is propelling the segmental market demand.

• The hospitals segment accounted for the dominant market share of around 43.5% in 2024 and is projected to grow at a substantial CAGR during the forecast period.

Based on the end user, the advanced molecular nuclear imaging market is divided into hospitals, imaging centers, academic and research centers, and others. Among these, the hospitals segment accounted for the dominant market share of around 43.5% in 2024 and is projected to grow at a substantial CAGR during the forecast period. The devices are used for providing detailed, 3D images of internal organ functions and physiological processes. Hospitals have extensive resources and infrastructure for integrating sophisticated nuclear imaging systems, which cater to a broad spectrum of medical conditions.

Regional Segment Analysis of the Advanced Molecular Nuclear Imaging Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the advanced molecular nuclear imaging market over the predicted timeframe.

North America is anticipated to hold the largest share of around 41.2% in the advanced molecular nuclear imaging market over the predicted timeframe. The market ecosystem in North America is strong, with the introduction of advanced products by the major industrial heavyweights well-represented. For instance, in July 2024, Positron Corporation, a leading molecular imaging medical device company offering PET & PET-CT imaging systems, presenting its NeuSight PET-CT 3D 64 slice scanner, available for North American market. The demand for advanced molecular nuclear imaging has been driven by the region's increasing demand for nuclear imaging and growing technological advancements. The U.S. is holding the largest share within the region, with around 85.0% share, owing to the presence of advanced medical facilities, use of high-end diagnostic imaging systems, and strong clinical research.

Asia Pacific is expected to grow at a rapid CAGR of about 10.0% in the advanced molecular nuclear imaging market during the forecast period. The Asia Pacific area has a thriving market for advanced molecular nuclear imaging due to its key trends, including integration of artificial intelligence, thermostatic and nuclear medicine practice in the region, as well as expanded isotope production.  With an increasing technological advancement, rising diagnostic applications across various diseases like cancer and cardiovascular diseases are primarily propelling the advanced molecular nuclear imaging market. China holds the dominant position in the Asia Pacific advanced molecular nuclear imaging market, accounting for about 14.5% CAGR during the forecast period. This is driven by the rapid growth in the PET/CT imaging systems, healthcare spending, with an increasing prevalence of cancer & other chronic diseases that need molecular nuclear diagnostics.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the advanced molecular nuclear imaging market, along with a comparative evaluation primarily based on their type of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes type development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Siemens Healthcare Private Limited
• Koninklijke Philips N.V.
• GENERAL ELECTRIC
• Neusoft Corporation
• Mediso Ltd.
• TTG IMAGING SOLUTIONS
• CMR Naviscan
• SurgicEye GmbH
• DDD-Diagnostic A/S
• Nordion (Canada) Inc.
• Cardinal Health
• Bracco
• Lantheus
• Jubilant Pharma Limited
• Novartis AG
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs) 

Recent Development

• In March 2026, MedGenome announced a majority investment in Mumbai-headquartered Medcare Management Services Pvt. Ltd., a radiology and nuclear medicine company known for its PET-CT and advanced molecular imaging services.

• In January 2026, Sheba to inaugurate Roman Abramovich Theranostics and Nuclear Medicine Center. The 4,700-square-meter facility at Tel Hashomer will include an on-site cyclotron and advanced imaging and targeted-treatment units, the medical center said.

• December 2025, TeamBest Global urged SNMMI Board and President Dr. Prabhu Ethiraj to enhance collaboration for advancing theranostics and expanding cancer diagnosis and treatment choices.

• In October 2025, United Imaging, a global manufacturer of cutting-edge medical imaging technology, showcases its most advanced AI-powered molecular imaging innovations, the uMI Panvivo family and the uMI Panorama family, and highlights the company's strong growth and confidence in the European market.   

• In June 2025, GE HealthCare’s commitment to advancing precision care in cardiology through its molecular imaging solutions would be on display at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting in New Orleans, Louisiana.

• In December 2024, Siemens Healthineers concluded the acquisition from Novartis of Advanced Accelerator Applications Molecular Imaging, a European manufacturing and distribution network of diagnostic radiopharmaceuticals for positron emission tomography (PET) scans.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the advanced molecular nuclear imaging market based on the below-mentioned segments:  

Global Advanced Molecular Nuclear Imaging Market, By Product

• SPECT Systems
• Hybrid PET Systems
• Planar Scintigraphy

Global Advanced Molecular Nuclear Imaging Market, By Application

• Oncology
• Cardiology
• Neurology
• Others

Global Advanced Molecular Nuclear Imaging Market, By End User

• Hospitals
• Imaging Centers
• Academic and Research Centers
• Others

Global Advanced Molecular Nuclear Imaging Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico

• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific

• South America
  • Brazil
  • Argentina
  • Rest of South America

• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa